Gender Disparity in Swiss Obesity Treatment Revealed

A new report from the Swiss Health Observatory (Obsan) has uncovered a significant gender imbalance in the use of weight-loss medications in Switzerland. Despite obesity being more common among men, women are prescribed new anti-obesity drugs, like Wegovy, at a rate nearly 2.5 times higher. This finding raises questions about the social and clinical factors influencing healthcare-seeking behaviours and treatment for obesity in the country.

The data reveals a stark contrast between obesity rates and medication usage. In Switzerland, 52% of men are classified as overweight or obese, compared to 34% of women. However, the consumption of GLP-1 drugs, a class of medications used for weight loss, tells a different story. In 2024, women consumed these drugs at a rate of 6.9 daily doses per 1,000, while men's consumption was only 2.8 daily doses per 1,000. This disparity highlights that the population with the higher medical need is not the one receiving the most treatment.

Clinical observations align with the statistical data. Dr. Philipp Gerber, head of the Obesity Centre at the University Hospital of Zurich, notes that significantly more women than men seek assistance at specialised weight-loss clinics. He suggests a key reason for this is that 'Women are more likely to be concerned about appearance.' This indicates that societal pressures and beauty standards may play a substantial role in motivating women to seek medical solutions for weight management more actively than men, even when the medical need, based on obesity statistics, is lower.

The popularity of these new weight-loss drugs has a significant financial dimension. Demand surged following the introduction of partial reimbursement by Swiss health insurers in spring 2024. In the first ten months alone, approximately 40,000 patients had these drugs covered, costing the healthcare system around CHF 43 million. The health insurance association PrioSwiss has warned that the annual costs could eventually escalate to as much as CHF 300 million, posing a considerable challenge for healthcare funding.

This gendered trend in obesity treatment may also reflect a wider pattern in Swiss healthcare. According to 2020 data from the Federal Statistical Office, women accounted for 56% of the nation's total health expenditure, with men accounting for 44%. While factors like maternity care and women's longer life expectancy contribute to this gap, the new data on weight-loss drugs suggests that a greater willingness to seek medical treatment, particularly when influenced by appearance, is an increasingly significant factor in this disparity.